In a bid to acquire a foothold in low-cost generics, the Japanese firm paid 737 rupees a share last June, forking out a premium of 31% to the company's stock price at the time. (See Daiichi Sankyo Decides Generics Are Healthy Biz).
In June, Express Scripts, one of the biggest managers of pharmacy benefits in the U.S., told its clients that Celebrex and Vioxx provide only a narrow benefit over ibuprofen (the branded version is Advil) and naproxen (Aleve), which, as generics, are vastly cheaper (see box).